SCHEMBL2098348

SCHEMBL2098348

O=C(O)N(c1ccccc1)c1ccccc1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.56
PTGIR P43119 2/20 0.44
TDP1 Q9NUW8 2/20 0.43
ALDH1A1 P00352 5/20 0.42
RAB9A P51151 3/20 0.42
KMT2A Q03164 2/20 0.42
NPC1 O15118 2/20 0.42
HTT P42858 2/20 0.42
POLB P06746 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
ATM Q13315 1/20 0.41
ESR1 P03372 1/20 0.41
ESR2 Q92731 1/20 0.41
KDM4E B2RXH2 2/20 0.40
AGTR2 P50052 1/20 0.40
TRPM8 Q7Z2W7 1/20 0.39
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
CES2 O00748 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2093031 0.87 PTGIR (0.51) NPSR1PTGIRTDP1ALDH1A1RAB9A
SCHEMBL2098346 0.86 NPSR1 (0.54) NPSR1PTGIRTDP1ALDH1A1RAB9A
SCHEMBL28149385 0.85 NPSR1 (0.52) NPSR1PTGIRTDP1ALDH1A1RAB9A
SCHEMBL1118587 0.85 NPSR1 (0.52) NPSR1PTGIRTDP1ALDH1A1RAB9A
SCHEMBL12272679 0.85 L3MBTL1 (0.52) NPSR1PTGIRTDP1ALDH1A1RAB9A
SCHEMBL2095981 0.84 ESR1 (0.48) NPSR1PTGIRTDP1ALDH1A1RAB9A
SCHEMBL2093494 0.82 NPSR1 (0.48) NPSR1TDP1ALDH1A1RAB9AKMT2A
SCHEMBL10575876 0.82 NPSR1 (0.48) NPSR1PTGIRTDP1ALDH1A1RAB9A
SCHEMBL10575306 0.80 NPC1 (0.68) NPSR1PTGIRTDP1ALDH1A1RAB9A
SCHEMBL5816665 0.80 NPSR1 (0.47) NPSR1PTGIRTDP1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 NPSR1 202/4885PTGIR 1605/4885TDP1 4548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.